Avalyn Pharma completes enrollment of 375 patients in Phase 2b MIST trial

Avalyn Pharma announced completion of target enrollment in its Phase 2b MIST clinical trial evaluating AP01 (inhaled pirfenidone) for progressive pulmonary fibrosis, with topline results expected in H2 2027. The milestone demonstrates strong investigator and patient demand for new PPF treatment options and represents a key clinical development step for the company's lead candidate.